Article Information
History
- April 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jineta Banerjee1,
- Jan M. Friedman2,
- Laura J. Klesse3,
- Kaleb Yohay4,
- Children’s Tumor Foundation Clinical Care Advisory Board,
- Justin T Jordan5,
- Scott Plotkin6,
- Robert J Allaway1,* and
- Jaishri Blakeley7,*
- 1Sage Bionetworks, Seattle, WA
- 2Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC
- 3Department of Pediatrics and Neurosurgery, Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
- 4Comprehensive Neurofibromatosis Center at NYU Langone Health, New York, NY
- 5Department of Neurology, Massachusetts General Hospital, Boston, MA
- 6Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA
- 7Departments of Neurology, Oncology, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD
- ↵*co-corresponding authors
Posted April 01, 2022.
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
